The Guardian features an interview with Moncef Slaoui, now chair of research and development at GlaxoSmithKline, who discusses his 23-year involvement in the research leading to the RTS,S malaria vaccine that has shown to halve the risk of malaria among African children. Slaoui said cellular immunity is the key to the vaccine’s success and research on the vaccine has advanced the company’s knowledge of adjuvants, substances that stimulate the immune system, which has allowed the development of other vaccines (Boseley, 10/19).